Clinical Evidence: Constipation Rates in Both Treatments
Understanding Constipation on Wegovy Compared to Mounjaro
When researching constipation on Wegovy versus Mounjaro, it's important to understand that both medications work through similar pathways that can affect digestive function. Wegovy (semaglutide) acts as a GLP-1 receptor agonist, whilst Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors, creating a dual-hormone approach. Clinical trial data shows constipation occurs in approximately 24% of Wegovy patients compared to 21% of Mounjaro patients, suggesting comparable rates between treatments. The difference in mechanisms may influence individual responses, which is why having access to both options through EverydayMeds provides valuable flexibility for your prescriber.
The onset and severity of constipation on Wegovy typically follows dose escalation patterns, often appearing during the first month as your body adjusts to treatment. Mounjaro shows similar timing, with most patients experiencing digestive adjustments during initial dose increases from 2.5mg to 5mg. Both medications slow gastric emptying as part of their weight management mechanism, which naturally affects bowel movement frequency. Understanding these patterns helps set realistic expectations and emphasises why clinical monitoring through our GPhC-registered pharmacy service (#9012878) proves essential for optimal outcomes.
Pricing Comparison: Wegovy vs Mounjaro Treatment Costs
EverydayMeds offers transparent pricing for both treatments, allowing direct cost comparison during your decision-making process. Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing to £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the 2.4mg maintenance dose. Our Intro Duo bundle combines your first two doses (0.25mg and 0.5mg) for £169.99, providing eight weeks of treatment with convenient delivery scheduling. New customers benefit from discount code FIRST40, whilst returning customers use DOSE25, both applied automatically at checkout to reach these final prices.
Mounjaro follows a different dose progression with six available strengths from 2.5mg to 15mg, each priced competitively within our weight management collection. Bundle options provide convenience for longer-term treatment planning, though individual circumstances determine the most suitable approach for managing constipation on Wegovy or Mounjaro. Your prescriber can factor treatment costs alongside clinical suitability when recommending the optimal choice. Both treatments represent significant investment in your health journey, supported by our clinical team throughout your experience.
Clinical Evidence from STEP Trials and Constipation Data
The landmark STEP trials provide comprehensive safety data regarding constipation on Wegovy across different patient populations. In clinical trials, patients taking Wegovy alongside diet and exercise reported constipation as a mild to moderate side effect in most cases, typically resolving within 4-8 weeks of reaching stable doses. Research published by Wilding et al., NEJM, 2021, demonstrated that digestive side effects, including constipation, were generally transient and manageable with appropriate clinical support.
Comparative analysis suggests both Wegovy and Mounjaro share similar constipation profiles, though individual responses vary significantly based on personal health factors. The STEP trials' safety data supports Wegovy's MHRA approval for weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities. This evidence-based approach to understanding constipation on Wegovy helps patients make informed decisions alongside their healthcare providers.
How Wegovy Works: GLP-1 Mechanism and Digestive Effects
Wegovy functions as a GLP-1 receptor agonist, mimicking your body's natural incretin hormones that regulate appetite and gastric emptying. This mechanism promotes feelings of fullness after smaller meals whilst reducing food cravings through direct action on brain appetite centres. The slower gastric emptying that contributes to satiety naturally affects bowel movement timing, explaining why constipation on Wegovy occurs as part of the therapeutic process. Weekly injections using the FlexTouch pen system provide consistent medication levels, supporting steady appetite management throughout your treatment. Understanding this mechanism helps contextualise digestive changes as expected physiological responses rather than concerning side effects. Your body typically adapts to these changes within the first month of reaching each new dose level during the mandatory escalation schedule.
Ordering Process: Clinical Assessment to Delivery
Accessing both Wegovy and Mounjaro through EverydayMeds begins with our comprehensive 3-minute online clinical assessment, designed to evaluate your suitability for weight management treatment. Our qualified prescribers review your submission within 3 working days (or 24 hours with express service), considering factors like previous constipation history and current medications that might influence your experience. Once approved, your prescription-only medicine arrives via next-day cold-chain delivery, maintaining the 2-8°C storage requirements essential for medication efficacy. This regulated process ensures appropriate clinical oversight while providing convenient access to both treatment options. Our GPhC-registered pharmacy service (#9012878) maintains full compliance with UK pharmaceutical regulations throughout your treatment journey. The seamless process from assessment to delivery supports consistent treatment adherence, crucial for managing any side effects including constipation on Wegovy or Mounjaro.
Storage and Practical Considerations for Travel
Storage requirements present a practical advantage when comparing constipation on Wegovy versus Mounjaro for active lifestyles. Wegovy maintains stability for 6 weeks at room temperature below 30°C once removed from refrigeration, significantly exceeding Mounjaro's 21-day room temperature limit. This extended stability proves valuable for business travel, holidays, or situations where refrigeration access is limited. The FlexTouch pen system provides reliable dose delivery with clear visual confirmation of injection completion, supporting consistent treatment that minimises digestive disruption. Proper storage maintains medication potency, ensuring consistent therapeutic levels that support your body's adaptation to treatment. These practical considerations may influence treatment choice, particularly for patients concerned about maintaining routine administration while managing initial side effects like constipation.
Managing Constipation: Wegovy vs Mounjaro Patient Strategies
Clinical experience suggests constipation on Wegovy responds well to proactive management strategies, including increased fibre intake, adequate hydration, and regular physical activity as part of your prescribed lifestyle modifications. The gradual dose escalation protocol allows your digestive system to adapt progressively, often reducing the severity of constipation compared to rapid treatment initiation. Mounjaro's dual-hormone mechanism may offer different constipation patterns, with some patients reporting more predictable digestive adjustment periods. Both treatments benefit from consistent meal timing and adequate fluid intake, supporting natural bowel function alongside the medications' appetite-suppressing effects.
Your EverydayMeds clinical team provides ongoing support for managing constipation on Wegovy or Mounjaro, with access to specialist advice when needed. The choice between treatments may partially depend on your previous experience with digestive medications and personal tolerance for temporary lifestyle adjustments. Both medications require commitment to dietary modifications that can positively influence constipation management while supporting overall treatment success. This comprehensive approach addresses both weight management goals and digestive comfort throughout your treatment journey.
Expert Prescriber Guidance: Choosing Between Treatments
Making an informed choice between Wegovy and Mounjaro requires expert clinical assessment that considers your individual risk factors for constipation alongside overall treatment suitability. Our qualified prescribers evaluate factors including previous digestive sensitivities, current medications, and lifestyle factors that influence treatment selection and monitoring requirements. Both treatments require prescription-only medicine protocols with ongoing clinical supervision, ensuring appropriate response to any side effects including constipation on Wegovy or alternative experiences with Mounjaro. The decision ultimately rests on clinical evidence, personal health factors, and practical considerations like storage requirements and cost implications. EverydayMeds provides access to both options through our regulated pharmacy service, supporting flexible prescriber choice based on your individual needs. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment, with expert guidance throughout your treatment selection and ongoing management process.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
